Bronchitis Treatment Market by Drug Class and Geography - Forecast and Analysis 2022-2026

Published: Mar 2022

Pages: 120

SKU: IRTNTR72547

Snapshot

The bronchitis treatment market share is expected to increase by USD 1.12 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.76%.

This bronchitis treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers bronchitis treatment market segmentation by drug class (antibiotics, anti inflammatory drugs, and bronchodilator) and geography (North America, Europe, Asia, and Rest of World (ROW)). The bronchitis treatment market report also offers information on several market vendors, including Akorn Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Cipla Ltd., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.

What will the Bronchitis Treatment Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Bronchitis Treatment Market Size for the Forecast Period and Other Important Statistics

Bronchitis Treatment Market: Key Drivers, Trends, and Challenges

The increasing prevalence of smoking is notably driving the bronchitis treatment market growth, although factors such as the high cost of healthcare may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the bronchitis treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Bronchitis Treatment Market Driver

The increasing prevalence of smoking is one of the key drivers supporting the bronchitis treatment market growth. According to CDC, in 2020, around 32.51 million consumers in the US used cigarettes. The prevalence of smoking in Canada was 12%, approximately 3.7 million consumers in 2020. This can be attributed to the increasing adoption of e-cigarettes and other chewable tobacco products in North America. Moreover, the UAE allows smoking in public places such as government facilities, restaurants, pubs and bars, public transport, and indoor offices. In South Africa, there were around 6 million smokers in 2019. Public smoking in South Africa has no stringent regulations. Therefore, the prevalence of smoking is much higher in the country. Thus, the increasing prevalence of smoking leads to increased cases of chronic bronchitis. Such factors will positively impact the growth of the global bronchitis treatment market during the forecast period.

Key Bronchitis Treatment Market Trend

Increased healthcare spending worldwide is another factor supporting the bronchitis treatment market growth. The governments of developed nations, such as the US, Germany, France, and Sweden, have increased their healthcare expenditure in recent years. According to the WHO, the global spending on healthcare continually increased between 2000 and 2018 and reached $8.3 trillion or 10% of global GDP. For instance, in 2020, the US spent 19.7% of its GDP on healthcare expenditure. Other European nations such as Germany, France, Sweden, and Austria spent 11.43%, 11.26%, 10.90%, and 10.33%, respectively, of their GDP on healthcare expenditure. The expenditure on prescription drugs and over-the-counter medicines has increased in recent years. Thus, increasing expenditure in the global healthcare sector and the increase in government aid to healthcare providers will drive the growth of the global bronchitis treatment market during the forecast period.

Key Bronchitis Treatment Market Challenge

The high cost of healthcare is one of the factors hindering the bronchitis treatment market growth. For instance, in 2019, the per capita healthcare expenditure was $7,138 in Switzerland, $6,748 in Norway, and $6,731 in Germany. The high cost of healthcare in these developed countries prevents patients from opting for treatment options for bronchitis. Additionally, in developing countries such as India, China, Brazil, Argentina, and others, due to lack of resources and low per capita income, patients cannot use drugs to treat bronchitis. The absence of proper healthcare infrastructure and less amount government aids received in the form of medical expense reimbursement further pose a challenge for the patients in these countries. Thus, the global per capita healthcare cost is expected to increase during the forecast period. Such factors will negatively impact the growth of the global bronchitis treatment market during the forecast period.

This bronchitis treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global bronchitis treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the bronchitis treatment market during the forecast period.

Who are the Major Bronchitis Treatment Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

This statistical study of the bronchitis treatment market encompasses successful business strategies deployed by the key vendors. The bronchitis treatment market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The bronchitis treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Bronchitis Treatment Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the bronchitis treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Bronchitis Treatment Market?

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for bronchitis treatment market in North America. Market growth in this region will be faster than the growth of the market in ROW.

The advanced healthcare infrastructure in the region will facilitate the bronchitis treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the COVID-19 pandemic negatively impacted the regional bronchitis treatment market. However, in H2 2020, the number of COVID-19 cases decreased with the introduction of vaccines in the region. This has led to the resumption of supply chain activities by regional vendors, which has resulted in the availability of various medications for the treatment of bronchitis. Such factors will contribute to the growth of the bronchitis treatment market during the forecast period.

What are the Revenue-generating Drug Class Segments in the Bronchitis Treatment Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The bronchitis treatment market share growth by the antibiotics segment will be significant during the forecast period. For example, Levofloxacin is an antibiotic that is used to kill the bacteria that cause infections and lead to conditions such as bronchitis. Vendors such as Teva Pharmaceutical Industries Ltd. offer Levofloxacin 500 mg film-coated tablets to treat infections of the lungs in patients with long-term breathing problems or pneumonia. Thus, the availability of a wide range of antibiotic treatment options for treating bronchitis will drive the growth of the market segment during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the bronchitis treatment market size and actionable market insights on post COVID-19 impact on each segment.

You may be interested in:

Antibiotics market - The market share is expected to increase by USD 4.44 billion from 2019 to 2024, and the market's growth momentum will accelerate at a CAGR of 3.03%.

Lung Cancer Therapeutics market - The market share has the potential to grow by USD 6.79 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.47%.

Bronchitis Treatment Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 4.76%
Market growth 2022-2026	$ 1.12 billion
Market structure	Fragmented
YoY growth (%)	2.96
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 40%
Key consumer countries	US, Canada, Australia, New Zealand, and Germany
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Akorn Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Cipla Ltd., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Bronchitis Treatment Market Report?

CAGR of the market during the forecast period 2022-2026
Detailed information on factors that will drive bronchitis treatment market growth during the next five years
Precise estimation of the bronchitis treatment market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the bronchitis treatment industry across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market's competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of bronchitis treatment market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 12: Market segments

3.3 Market size 2021

3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

4.2 Bargaining power of buyers
- Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Drug Class

5.1 Market segments
- Exhibit 24: Chart on Drug Class - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Drug Class - Market share 2021-2026 (%)

5.2 Comparison by Drug Class
- Exhibit 26: Chart on Comparison by Drug Class
- Exhibit 27: Data Table on Comparison by Drug Class

5.3 Antibiotics - Market size and forecast 2021-2026
- Exhibit 28: Chart on Antibiotics - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Antibiotics - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Antibiotics - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Antibiotics - Year-over-year growth 2021-2026 (%)

5.4 Anti inflammatory Drugs - Market size and forecast 2021-2026
- Exhibit 32: Chart on Anti inflammatory Drugs - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Anti inflammatory Drugs - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Anti inflammatory Drugs - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Anti inflammatory Drugs - Year-over-year growth 2021-2026 (%)

5.5 Bronchodilator - Market size and forecast 2021-2026
- Exhibit 36: Chart on Bronchodilator - Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Bronchodilator - Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Bronchodilator - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Bronchodilator - Year-over-year growth 2021-2026 (%)

5.6 Market opportunity by Drug Class
- Exhibit 40: Market opportunity by Drug Class ($ million)

6 Customer Landscape

6.1 Customer landscape overview
- Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

7.1 Geographic segmentation
- Exhibit 42: Chart on Market share by geography 2021-2026 (%)
- Exhibit 43: Data Table on Market share by geography 2021-2026 (%)

7.2 Geographic comparison
- Exhibit 44: Chart on Geographic comparison
- Exhibit 45: Data Table on Geographic comparison

7.3 North America - Market size and forecast 2021-2026
- Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)

7.4 Europe - Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)

7.5 Asia - Market size and forecast 2021-2026
- Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

7.7 US - Market size and forecast 2021-2026
- Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)

7.8 Canada - Market size and forecast 2021-2026
- Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%)

7.9 Germany - Market size and forecast 2021-2026
- Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)

7.10 Australia - Market size and forecast 2021-2026
- Exhibit 74: Chart on Australia - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Australia - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Australia - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Australia - Year-over-year growth 2021-2026 (%)

7.11 New Zealand - Market size and forecast 2021-2026
- Exhibit 78: Chart on New Zealand - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on New Zealand - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on New Zealand - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on New Zealand - Year-over-year growth 2021-2026 (%)

7.12 Market opportunity by geography
- Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

8.1 Market drivers

8.2 Market challenges

8.3 Impact of drivers and challenges
- Exhibit 83: Impact of drivers and challenges in 2021 and 2026

8.4 Market trends

9 Vendor Landscape

9.1 Overview

9.2 Vendor landscape
- Exhibit 84: Overview on Criticality of inputs and Factors of differentiation

9.3 Landscape disruption
- Exhibit 85: Overview on factors of disruption

9.4 Industry risks
- Exhibit 86: Impact of key risks on business

10 Vendor Analysis

10.1 Vendors covered
- Exhibit 87: Vendors covered

10.2 Market positioning of vendors
- Exhibit 88: Matrix on vendor position and classification

10.3 AstraZeneca Plc
- Exhibit 89: AstraZeneca Plc - Overview
- Exhibit 90: AstraZeneca Plc - Product / Service
- Exhibit 91: AstraZeneca Plc - Key news
- Exhibit 92: AstraZeneca Plc - Key offerings

10.4 Bayer AG
- Exhibit 93: Bayer AG - Overview
- Exhibit 94: Bayer AG - Business segments
- Exhibit 95: Bayer AG - Key news
- Exhibit 96: Bayer AG - Key offerings
- Exhibit 97: Bayer AG - Segment focus

10.5 Boehringer Ingelheim International GmbH
- Exhibit 98: Boehringer Ingelheim International GmbH - Overview
- Exhibit 99: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 100: Boehringer Ingelheim International GmbH - Key news
- Exhibit 101: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 102: Boehringer Ingelheim International GmbH - Segment focus

10.6 Cipla Ltd.
- Exhibit 103: Cipla Ltd. - Overview
- Exhibit 104: Cipla Ltd. - Business segments
- Exhibit 105: Cipla Ltd. - Key news
- Exhibit 106: Cipla Ltd. - Key offerings
- Exhibit 107: Cipla Ltd. - Segment focus

10.7 Dr. Reddys Laboratories Ltd.
- Exhibit 108: Dr. Reddys Laboratories Ltd. - Overview
- Exhibit 109: Dr. Reddys Laboratories Ltd. - Business segments
- Exhibit 110: Dr. Reddys Laboratories Ltd. - Key offerings
- Exhibit 111: Dr. Reddys Laboratories Ltd. - Segment focus

10.8 GlaxoSmithKline Plc
- Exhibit 112: GlaxoSmithKline Plc - Overview
- Exhibit 113: GlaxoSmithKline Plc - Business segments
- Exhibit 114: GlaxoSmithKline Plc - Key news
- Exhibit 115: GlaxoSmithKline Plc - Key offerings
- Exhibit 116: GlaxoSmithKline Plc - Segment focus

10.9 Lupin Ltd.
- Exhibit 117: Lupin Ltd. - Overview
- Exhibit 118: Lupin Ltd. - Product / Service
- Exhibit 119: Lupin Ltd. - Key news
- Exhibit 120: Lupin Ltd. - Key offerings

10.10 Merck and Co. Inc.
- Exhibit 121: Merck and Co. Inc. - Overview
- Exhibit 122: Merck and Co. Inc. - Business segments
- Exhibit 123: Merck and Co. Inc. - Key news
- Exhibit 124: Merck and Co. Inc. - Key offerings
- Exhibit 125: Merck and Co. Inc. - Segment focus

10.11 Pfizer Inc.
- Exhibit 126: Pfizer Inc. - Overview
- Exhibit 127: Pfizer Inc. - Product / Service
- Exhibit 128: Pfizer Inc. - Key news
- Exhibit 129: Pfizer Inc. - Key offerings

10.12 Sanofi SA
- Exhibit 130: Sanofi SA - Overview
- Exhibit 131: Sanofi SA - Business segments
- Exhibit 132: Sanofi SA - Key news
- Exhibit 133: Sanofi SA - Key offerings
- Exhibit 134: Sanofi SA - Segment focus

11 Appendix

11.1 Scope of the report

11.2 Inclusions and exclusions checklist
- Exhibit 135: Inclusions checklist
- Exhibit 136: Exclusions checklist

11.3 Currency conversion rates for US$
- Exhibit 137: Currency conversion rates for US$

11.4 Research methodology
- Exhibit 138: Research methodology
- Exhibit 139: Validation techniques employed for market sizing
- Exhibit 140: Information sources

11.5 List of abbreviations
- Exhibit 141: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

bronchitis treatment market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis